Azora Therapeutics adds three directors, four board members resign

Azora Therapeutics, Inc., formerly known as Adial Pharmaceuticals, Inc., disclosed in an 8-K that on November 3, 2026 it appointed three new directors to its board. Aida Habtezion, M.D., Paul Hastings and Thomas Soloway joined the board, with Habtezion seated as a Class I director with a term through the 2028 annual meeting and Hastings and Soloway seated as Class II directors with terms through the 2029 annual meeting.¹ The board determined that each of the three new directors is independent under Nasdaq listing standards.¹

Habtezion previously served as Chief Medical Officer and Head of Worldwide Medical & Safety at Pfizer.¹ Hastings is Chief Executive Officer of Nkarta.¹ Soloway is Chief Executive Officer of T-knife Therapeutics.¹

The board also reshuffled its committees, naming Soloway as chair of the audit committee, Wendy Young, Ph.D. as chair of the compensation committee, and Hastings as chair of the nominating and corporate governance committee.¹

Separately, J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland and Kevin Schuyler resigned from the board effective November 3, 2026, after which Matthew Davidson was appointed board chair and the board was reduced to five members.¹ The company said the resignations did not stem from any disagreement over operations, policies or practices.¹

In a related disclosure, the filing noted that shareholders had approved conversion of Series A Non-Voting Convertible Preferred Stock issued to former Azora Therapeutics stockholders in connection with the June 11, 2026 acquisition, and that 9,924.260 shares of that preferred stock converted into 9,924,260 shares of common stock effective November 2, 2026 at 5:00 p.m. Eastern time.¹ Following the conversion, the company reported 14,243,129 shares of common stock outstanding as of November 4, 2026.¹